Related Experiment Videos

Acute promyelocytic leukemia: from highly fatal to highly curable

Zhen-Yi Wang1, Zhu Chen

  • 1Shanghai Institute of Hematology and State Key Laboratory of Medical Genomics, Riu Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Road II, Shanghai, China. xiejx@publicsta2.sta.net.cn

Blood
|February 27, 2008
PubMed

Insights

Acute promyelocytic leukemia (APL), a severe leukemia subtype, has seen improved outcomes with targeted therapies. All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) significantly increase remission rates and survival for APL patients.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute promyelocytic leukemia (APL) is a highly aggressive subtype of acute myeloid leukemia (AML).
  • APL is characterized by a specific chromosomal translocation t(15;17) involving the PML and RARalpha genes.
  • Historically, chemotherapy offered limited cure rates for APL, with a high risk of bleeding and rapid fatality.

Observation:

  • Chemotherapy (CT) achieved complete remission (CR) in 75-80% of newly diagnosed APL patients, but long-term survival was poor.
  • Median remission duration with CT was 11-25 months, with only 35-45% of patients cured.
  • The introduction of all-trans retinoic acid (ATRA) revolutionized APL treatment.

Findings:

  • ATRA-based regimens increased CR rates to 90-95% and 5-year disease-free survival (DFS) to 74%.
  • Arsenic trioxide (ATO) further improved outcomes for both newly diagnosed and relapsed/refractory APL.
  • Combined ATRA and ATO represent a highly effective targeted therapy for APL.

Implications:

  • APL serves as a paradigm for targeted cancer therapy, demonstrating the power of understanding molecular mechanisms.
  • ATRA and ATO have transformed APL from a fatal disease to a curable one for most patients.
  • Further research into the mechanisms of ATRA and ATO can inform other cancer treatments.

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...